Harvinder S Sandhu1, Safdar N Khan. 1. Spinal Surgical Service, Hospital for Special Surgery, New York, New York 10021, USA.
Abstract
STUDY DESIGN: A review of the rationale behind the use of animal models for the assessment of bone morphogenetic proteins (BMPs) in the spine. OBJECTIVE: To summarize the underlying principles of animal experimentation in the context of bone morphogenetic proteins and the spine. SUMMARY OF BACKGROUND DATA: Animal models aid in the collection of important information regarding the precise mechanobiologic events that occur during spinal fusion healing. Reproducible spinal fusion models have been developed in several animal species, leading to experimentation in a controlled fashion. Reliable assessment of outcome measures for osseous healing, including histology and biomechanical testing, has made preclinical testing of innovative growth factors essential before the advance to clinical trials. METHODS: These materials have initially gone through the "burden of proof" steps: proof of concept studies, feasibility studies, and efficacy studies. RESULTS AND CONCLUSIONS: Bone morphogenetic proteins have undergone extensive scrutiny in the preclinical arena. This article summarizes the evolution of animal experimentation with BMP including the background and future directions.
STUDY DESIGN: A review of the rationale behind the use of animal models for the assessment of bone morphogenetic proteins (BMPs) in the spine. OBJECTIVE: To summarize the underlying principles of animal experimentation in the context of bone morphogenetic proteins and the spine. SUMMARY OF BACKGROUND DATA: Animal models aid in the collection of important information regarding the precise mechanobiologic events that occur during spinal fusion healing. Reproducible spinal fusion models have been developed in several animal species, leading to experimentation in a controlled fashion. Reliable assessment of outcome measures for osseous healing, including histology and biomechanical testing, has made preclinical testing of innovative growth factors essential before the advance to clinical trials. METHODS: These materials have initially gone through the "burden of proof" steps: proof of concept studies, feasibility studies, and efficacy studies. RESULTS AND CONCLUSIONS: Bone morphogenetic proteins have undergone extensive scrutiny in the preclinical arena. This article summarizes the evolution of animal experimentation with BMP including the background and future directions.
Authors: Gajadhar Bhakta; Bina Rai; Zophia X H Lim; James H Hui; Gary S Stein; Andre J van Wijnen; Victor Nurcombe; Glenn D Prestwich; Simon M Cool Journal: Biomaterials Date: 2012-06-09 Impact factor: 12.479
Authors: Stephen D Cook; Laura P Patron; Samantha L Salkeld; Kirk E Smith; Bruce Whiting; Robert L Barrack Journal: Clin Orthop Relat Res Date: 2009-12 Impact factor: 4.176
Authors: Andrew L Alejo; Scott McDermott; Yusuf Khalil; Hope C Ball; Gabrielle T Robinson; Ernesto Solorzano; Amanda M Alejo; Jacob Douglas; Trinity K Samson; Jesse W Young; Fayez F Safadi Journal: J Orthop Sports Med Date: 2022-09-05
Authors: Ashvin K Dewan; Rahul A Dewan; Nathan Calderon; Angie Fuentes; Zawaunyka Lazard; Alan R Davis; Michael Heggeness; John A Hipp; Elizabeth A Olmsted-Davis Journal: J Orthop Surg Res Date: 2010-08-21 Impact factor: 2.359
Authors: Jan Henkel; Maria A Woodruff; Devakara R Epari; Roland Steck; Vaida Glatt; Ian C Dickinson; Peter F M Choong; Michael A Schuetz; Dietmar W Hutmacher Journal: Bone Res Date: 2013-09-25 Impact factor: 13.567